Edgewise Therapeutics, Inc. Cash and Restricted Cash
Edgewise Therapeutics, Inc. (EWTX) had Cash and Restricted Cash of $72.32 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $72.32M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $33.21M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61.15M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46.00M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $72.32M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $33.21M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $61.15M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $46.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $43.40M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $49.92M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $41.67M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $44.81M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $43.48M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $30.26M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $86.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $32.96M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $31.81M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $48.23M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $21.99M 10-K · filed 2026-02-26 |
| 2022-09-30 | $109.75M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $18.34M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $34.45M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $15.57M 10-K · filed 2024-02-22 |
| 2021-09-30 | $10.57M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $50.40M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $221.04M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $104.92M 10-K · filed 2023-02-23 |
| 2019-12-31 | $23.65M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |